A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Tønnesen P, Tonstad S, Hjalmarson A, Lebargy F, van Spiegel PI, Hider A, Sweet R, Townsend J (Gentofte University Hospital, Gentofte, Denmark; Clinic for Preventive Medicine, Ullevål University Hospital, Oslo, Norway; Smoking Cessation Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden; Hospital Maison Blanche, Reims Cedex, France; Slotervaart Hospital, Amsterdam, The Netherlands; and GlaxoSmithKline Research and Development, Greenford, Middlesex, UK). A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation. J Intern Med 2003; 254: 184–192. Background. Bupropion sustained release (bupropion SR) has been shown to increase smoking cessation success rates in the US studies. Objective. To determine whether bupropion SR, in combination with counselling, is effective for smoking cessation in a multi‐country study. Methods. This randomized, double‐blind, placebo‐controlled trial enrolled 707 smokers. A total of 527 received bupropion SR 300 mg daily for 7 weeks and 180 received placebo. A total of 11 clinic visits and 10 telephone contacts were scheduled, during the course of 1 year. Seven‐week and 12‐month abstinence rates were the study outcomes. Results. Both continuous and weekly point prevalence smoking abstinence rates were significantly higher in the bupropion SR group compared with placebo. The continuous abstinence rate from weeks 4 to 7 was 46% in the bupropion SR group compared with 23% in the placebo group [odds ratio (OR) = 2.82; 95% confidence interval (CI) 1.89–4.28; P < 0.001). At month 12, the continuous abstinence rates were 21% for the bupropion SR group and 11% for the placebo group (OR = 2.19; 95% CI 1.29–3.86, P = 0.002). For most nicotine‐withdrawal symptoms small changes were measured. Adverse events were higher for the bupropion SR group compared with placebo (insomnia 24% vs. 15%; dry mouth 13% vs. 5%). Conclusion. Bupropion SR in combination with counselling increased the abstinence rate compared with placebo, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
The effect of bupropion on nicotine craving and withdrawal
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000) · Psychopharmacology · doi:10.1007/s002130050022 · Cited by 259
Gonzales, D. H., Nides, M. A., Ferry, L. H., Kustra, R. P., Jamerson, B. D., Segall, N., Herrero, L. A., Krishen, A., Sweeney, A., Buaron, K., et al. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115750 · Cited by 143
Cited by
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361
“The last 4 weeks of treatment end point was based on the precedent used for previous smoking cessation trials.(13,18) The 2 secondary end points were continuous abstinence rates from week 9 through week 24, and from week 9 through week 52.”
MethodResultLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
Wu, P., Wilson, K., Dimoulas, P., & Mills, E. J. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-300 · Cited by 484
Goodman, A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.030 · Cited by 413
Metadata
- Authors
- Tønnesen, P., Tonstad, S., Hjalmarson, A., Lebargy, F., Van Spiegel, P. I., Hider, A., Sweet, R., & Townsend, J.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2003-07-09
- Volume
- 254
- Issue
- 2
- Pages
- 184-192
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2078129420
- Cited by
- 143
- References
- 5
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation. https://app.cochat.ai/papers/10.1046/j.1365-2796.2003.01185.x
- The paper
- Tønnesen, P., Tonstad, S., Hjalmarson, A., Lebargy, F., Van Spiegel, P. I., Hider, A., Sweet, R., & Townsend, J. (2003). A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.2003.01185.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.